Advanced Inhalation Therapies Granted European Orphan Drug Designation for Nitric Oxide for the Treatment of Cystic Fibrosis

REHOVOT, Israel and NEW YORK, May 1, 2015 -- (Healthcare Sales & Marketing Network) -- Advanced Inhalation Therapies Ltd (AIT), a leading anti-microbial therapeutic company, announced that the European Commission, acting on the recommendation from the Com... Biopharmaceuticals, RegulatoryAdvanced Inhalation Therapies, AIT-CF, nitric oxide, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news